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among usual care group. In the unadjusted model, specialty care was associated
with lower risk of developing MS relapses with risk ratios (RR) of 0.813 for any
relapse, 0.765 for multiple relapses, hazard ratios (HR) of 0.727 for the first relapse,
0.782 for the second relapse. After adjusting for the demographics, socioeconom-
ics, comorbidities, and health services utilizations, specialty care was associated
with lower risk of MS relapses with RRs of 0.761 for any relapses, 0.712 for multiple
relapses; lower HRs of 0.674 for the first relapse, and of 0.741 for the second relapse,
compared to usual care. These measures are mostly statistically significant (P
0.05). CONCLUSIONS: Over the three-year study period, specialty care was associ-
ated with significantly lower risk for relapses, fewer MS relapses, and longer re-
lapse-free time.
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OBJECTIVES: To estimate the prevalence of drug-treated MS within the Brazilian
public healthcare system (BPHS) and compare it with published prevalence rates.
METHODS: A previously described method to estimate the prevalence of diseases
treated with drugs that are specific to them and must be taken continuously was
employed. The total amount of MS drugs (Glatiramer 20mg, Betainterferon 22mcg,
Betainterferon 44mcg, Betainterferon 30mcg, Betainterferon 300mcg) dispensed
from 2006 to 2009 was obtained from the Ambulatory Information Database and
the daily doses defined by BPHS MS guidelines were used to convert it in drug-
treated cases. The drug-treated prevalence was compared with rates achieved
through conventional cross-sectional studies (4.27-15/100,000). Complementary
analysis was performed using Brazilian private health plans coverage data.
RESULTS: The estimated drug-treated prevalent cases within the BPHS were 3,569
in 2006 with a constant increasing until 2009 when reached 6,099. Drug-treated
prevalence rates (per 100,000) were 1.93, 2.63, 3.08, and 3.21 in 2006, 2007, 2008, and
2009, respectively. MS prevalent cases in the BPHS were estimated as ranging from
7,838 in 2006 to 8,113 in 2009 using the 4.27/100,000 rate and from 27,533 in 2006 to
28,499 in 2009 using the 15/100,000 rate. The prevalence of MS estimated from drug
consumption data was found to be 24.8-78.6% lower than that estimated from
cross-sectional studies. Even when private health plans coverage (
20%) was con-
sidered, the difference remained substantial between drug-treated and BPHS prev-
alent cases (total prevalent cases minus those supposed to have private coverage).
In 2009, this difference ranges from 310 (BPHS cases minus drug-treated cases)
to 22,399 (prevalent cases using 15/100,000 minus drug-treated). CONCLUSIONS:
These findings raise important questions about barriers to access to MS treatment,
undertreatment and/or underdiagnosis of MS and the reliability of the available
prevalence rates for use in projecting eligible population and performing budget
impact analysis.
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OBJECTIVES: To investigate the incidence of subarachnoid hemorrhage(SAH) in
patients with unruptured intracranial aneurysm(UIA) in South Korea from
2006-2009. METHODS: A longitudinal study using national representative health
claim database including all hospital records for every Korean citizen was em-
ployed. We identified patients with UIA who were 18-80 years old using ICD-10
codes of I67.1 in 2006. To select eligible patients, history period was applied for one
year from first diagnosis of UIA (i.e. index date) in 2006. We excluded patients with
UIA diagnosis, SAH, or treatments(clip and coil) during history periods. Patients
with head trauma or brain tumor during study periods were also excluded. Eligible
patients were followed for at least 3 years from index date. SAH patients were
defined as ICD-10 codes of I60 excluding I60.8 with the hospitalization of14days
or death within 14days from hospitalization. Sensitivity analysis was conducted to
see the robustness using different definition of SAH. Additionally, the length of stay
of SAH was estimated using generalized linear model with log link and gamma
distribution. RESULTS: We identified 7404 eligible patients with UIA, including
1,466(20%) treated patients and 5,938(80%) untreated patients formedian follow-up of
3.4 years. For patients with untreated UIA, the incidence rate of SAH was 0.7/100per-
son-years(PYs) (133/5,934 patients). In the definition of SAH of all hospitalization, the
incidence rate increased by 1.3/100PYs. The incidence of SAH was highest in the first
year after first diagnosis of UIA. Mean length of stay of SAH was 30days(95%CI:24.0-
36.2) formales and 38days(95%CI:32.8-42.8) for females, respectively.CONCLUSIONS:
The rupture rate for untreated UIA patients were 0.7-1.3/100 PY from 2006-2009.
This study results indicate that careful follow-up for UIA patients is needed to
prevent rupture and decrease economic burden of SAH.
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OBJECTIVES: To determine the effect of Alzheimer patient’s characteristics and
medications on their functional dependence to carry out activities of daily living
(ADL).METHODS: Data for the present study was obtained from National Nursing
Home Survey (NNHS-2004). Alzheimer patients selected using ICD9-CM code of
331.00. Patients aged above 65 with completed Minimum Data Set (MDS) assess-
ment were included in the study. Long formMDS-ADL scale ranging from 0-28 that
comprises sevenADLwas used for the study. Patientswho scored less than 15were
considered independent, while those who scored between15-28 were considered
dependent. Multivariate logistic regression was carried out to determine the effect
of patient demographics, geriatric conditions, co-morbidities and medication use
on functional dependence. Statistical analysis performed using SAS 9.1. RESULTS:
Among 166,382 Alzheimer patients, 61,094 (58.02%) were functionally dependent.
Being female (OR  1.743; 95%CI  1.131 - 2.685), presence of urinary incontinence
(OR  3.212; 95%CI  2.093 - 4.928), bowel incontinence (OR  6.384; 95% CI  4.318 -
9.439), presence of physical restraint (OR  1.960; 95% CI  1.367 - 2.809) and, poor
nutrition (OR2.015; 95%CI 1.447 - 2.806) significantly increased the risk of func-
tional dependence. Co-morbidities such as depression (OR 1.546; 95%CI 1.042 -
2.293) and osteoporosis (OR 1.644; 95%CI  1.054 - 2.562) increased the risk of
functional dependence while use of cholinesterase inhibitor (ChEI) decreased the
risk of functional dependence (OR  0.466; 95%CI  0.348 - 0.622). CONCLUSIONS:
Factors such as incontinence, poor nutrition, co-morbidities and physical restraint
use, in addition to cognitive impairment, significantly affect ability of Alzheimer
patients to carry out ADL. A multidimensional approach that controls these risk
factors may help decrease functional dependence in carrying out ADL.
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OBJECTIVES: To estimate the incremental budgetary change in per-member-per-
month (PMPM)medical and pharmacy costs after the introduction of everolimus, a
mammalian target of rapamycin inhibitor, for the treatment of subependymal gi-
ant-cell astrocytomas (SEGA) in patients with tuberous sclerosis complex. In a
phase I/II trial, everolimus was associated with reduced SEGA volume and seizure
frequency.METHODS: Two-year budget impact analysis was conducted based on a
retrospective, longitudinal study of administrative claims that showed an increase
in healthcare costs in the years leading up to and after surgery for SEGA removal.
Based on the aforementioned trial, themodel assumed that patients using everoli-
mus did not require surgical intervention; however, to be conservative, no impact
on seizure frequency was assumed. Estimates of SEGA prevalence, adverse events,
drug costs, and monitoring costs were based on published sources. Sensitivity
analysis evaluated the impact of estimating annual treatment costs for patients
with continuous eligibility only. RESULTS: In a hypothetical 1,000,000-member
health plan, an estimated 5.9 patients with growing SEGAs require care. Prior to
introducing everolimus, estimated total cost for the treatment of growing SEGAs
was $0.022 PMPM for all plan members. After introducing everolimus, there were
0.9, 19.8, and 6.6 fewer claims per patient for inpatient hospitalizations, outpatient
visits, and other pharmaceutical use, respectively. While pharmacy cost increased
by $0.038 PMPM, the total medical and pharmacy costs increased by only $0.026,
due to fewer SEGA surgeries. Sensitivity analysis showed greater savings in medi-
cal spending after the introduction of everolimus, resulting in a total spending
increase of $0.022 PMPM. CONCLUSIONS: Increased pharmaceutical spending in
the first two years of everolimus use was partially offset by savings in medical
costs. Potential additional savings in anti-epileptic drug spending may further off-
set the costs.
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OBJECTIVES: We determined the prevalence of OSA in patients with the specific
components of the metabolic syndrome (hypertension, hyperlipidemia and diabe-
tes). We also explored the incremental burden of OSA on health care utilization in
patientswith the specific components of themetabolic syndrome.METHODS:Data
were obtained from the Maryland Medicaid database for January 2001 through June
2006. These data contain all claims records for medical inpatient, outpatient, and
pharmacy services submitted to the state.We assigned beneficiaries into groups: hav-
ing any one of the components of the metabolic syndrome, to a cohort called “one
disease” (n7,086). Having any two of the three components the cohort called “two
diseases” (n6,774). Having all of the three components the cohort called “three dis-
eases” (n5,925). Medical utilization data were collected from the index date through
theendof the studyor the last dateof service,whichever occurredfirst.RESULTS:The
likelihood of getting OSA by disease cohort- Beneficiaries with any two compo-
nents of the metabolic syndrome or all three components had 2.10 and 3.24 times
respectively the likelihood of developing OSA compared to those with one compo-
nent alone. The average annualized medical utilization by OSA status in each
cohort, adjusted for age, gender, race, obesity, CCI scores, and number of days in
cohort. Beneficiaries who had the concomitant diagnosis of OSA had a significantly
higher number ofmedical services claims than thosewithout OSA; physician office
visits accounted for the largest share of medical utilization, followed by outpatient
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